Testing QLS12010 safety in healthy adults and people with eczema
Treatments studied
Part of Bones, joints & muscles, Genetic & congenital, Immune system & allergy, Infections, Skin clinical trials.
This trial tests a new drug, QLS12010, to see if it is safe and how it works in healthy volunteers and in people with moderate to severe atopic dermatitis (eczema). It may offer a new treatment option for those whose eczema has not improved with topical creams.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For parts A-C: You are between 18 and 45 years old.
- For part D: You have moderate to severe eczema that has lasted at least 6 months and has not responded well to topical treatments.
- Your eczema covers at least 10% of your body, with a certain severity score (EASI score of 16 or higher, vIGA-AD score of 3 or higher).
- You have had significant itching (average weekly itch score of 4 or more) in the week before starting the drug.
- You do not have other serious health conditions, and you are not taking certain medications or supplements that might interfere with the study drug.
- You do not smoke more than 5 cigarettes a day, drink too much alcohol, or have donated blood recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, QLS12010, for people with moderate-to-severe rheumatoid arthritis who have not improved enough after trying at least two other types of RA medications.
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests a new medicine called BBT001, first in healthy people and then in adults with moderate to severe eczema (atopic dermatitis). It aims to see if the drug is safe and how well it works for treating eczema that hasn't improved with topical treatments.
This early-stage trial tests a new experimental medicine called REGN20423 in two groups: healthy volunteers and people with atopic dermatitis (a chronic skin condition causing itching and inflammation). The trial aims to assess whether the medicine is safe and well-tolerated.
This trial tests if a new medication, QL2108, works as well as the approved drug Dupixent for adults with moderate-to-severe atopic dermatitis (eczema). You may be able to join if you've had eczema for at least a year and have active symptoms covering a large area of your body.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.